425: Clearwater Analytics and Enfusion Announce Preliminary Results of Merger Consideration Election

Clearwater Analytics and Enfusion have announced the preliminary results of the election by Enfusion shareholders regarding the form of merger consideration they wish to receive in connection with Clearwater's acquisition of Enfusion.

Summary

• Clearwater Analytics and Enfusion announced preliminary results of the election by Enfusion shareholders regarding the form of merger consideration.
• The deadline for the election was April 16, 2025.
• The parties expect the transaction to close on April 21, 2025, pending shareholder approval and customary closing conditions.
• Enfusion shareholders could elect to receive per share mixed consideration, per share stock consideration, or per share cash consideration.
• The value paid per share of Enfusion Class A common stock will be equalized such that the value of the Merger Consideration will be substantially the same, regardless of which form of Merger Consideration is elected.
• Assuming the transaction closes on April 21, 2025, the Final Parent Stock Price is $23.2440, and the total number of Eligible Shares is expected to be 129,995,464.
• Based on these figures, the Per Share Parent Stock Amount would be 0.2159, the Aggregate Consideration would be $1,412,840,049.03, the Aggregate Consideration Per Share would be $10.87, the Per Share Cash Consideration would be $10.87, and the Exchange Ratio would be 0.4676.
• Preliminary results show that approximately 45.5% of Enfusion shareholders elected to receive the Per Share Mixed Consideration, 6.1% elected the Per Share Stock Consideration, 40.9% elected the Per Share Cash Consideration, and 7.6% did not make a valid election and will receive the Per Share Stock Consideration.
• The Per Share Cash Consideration option is oversubscribed and will be prorated.
• Final certified results are expected shortly before closing.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the announcement confirms the progression of the merger, but there are risks associated with integration and potential proration of the cash consideration.

Positives

• The merger is progressing as expected with a target closing date of April 21, 2025.
• The value of the merger consideration will be substantially the same regardless of the form elected, providing certainty for shareholders.

Negatives

• The Per Share Cash Consideration option is oversubscribed, meaning some shareholders who elected this option will receive a prorated amount.

Risks

• The transaction is subject to shareholder approval and customary closing conditions.
• The ability to successfully integrate the operations and technology of Enfusion with those of Clearwater is a risk.
• Retaining and incentivizing Enfusion employees after the acquisition is a risk.
• Retaining Enfusion's clients is a risk.
• Repaying debt incurred for the acquisition and meeting financial covenants is a risk.
• Cost savings, synergies, and growth from the acquisition may not be fully realized or may take longer to realize than expected.

Future Outlook

The parties expect to close the Transaction on April 21, 2025, subject to the approval of the Transaction by Enfusion shareholders and the satisfaction or waiver of other customary closing conditions.

Industry Context

This announcement reflects ongoing consolidation trends within the financial technology sector, as companies seek to broaden their service offerings and achieve greater scale.

Comparison to Industry Standards

• It is difficult to compare the results of the shareholder election to industry standards as this is specific to the terms of the merger agreement.
• However, the high percentage of shareholders making an election (over 92%) suggests strong engagement and awareness of the transaction.

Stakeholder Impact

• Enfusion shareholders will receive merger consideration in the form of cash and/or Clearwater stock.
• Clearwater shareholders may see dilution of their ownership depending on the final stock consideration.
• Employees of both companies face potential changes related to integration and restructuring.
• Customers of both companies may experience changes in service offerings and support.

Next Steps

• Enfusion shareholder vote on the transaction.
• Satisfaction or waiver of other customary closing conditions.
• Final determination of the merger consideration and allocation.
• Closing of the transaction expected on April 21, 2025.
• Integration of Enfusion's operations and technology with Clearwater.

Key Dates

Keywords

Merger Consideration, Enfusion, Clearwater Analytics, Acquisition, Shareholders, Transaction